| 401 | ECORelectroCore, Inc. |
32 mln USD |
-43,6% |
2025 |
| 402 | VSTMVerastem, Inc. |
30,9 mln USD |
-677,6% |
2025 |
| 403 | FHTXFoghorn Therapeutics Inc. |
30,9 mln USD |
-240,3% |
2025 |
| 404 | SCLXScilex Holding Co |
30,3 mln USD |
-1236,4% |
2025 |
| 405 | ICCCImmucell Corp |
27,6 mln USD |
-3,8% |
2025 |
| 406 | SRTSSensus Healthcare, Inc. |
27,5 mln USD |
-28,1% |
2025 |
| 407 | CUECue Biopharma, Inc. |
27,5 mln USD |
-96,9% |
2025 |
| 408 | TRDAEntrada Therapeutics, Inc. |
25,4 mln USD |
-565,5% |
2025 |
| 409 | MGXMetagenomi Therapeutics, Inc. |
25,2 mln USD |
-348,5% |
2025 |
| 410 | HYFTMindWalk Holdings Corp. |
24,5 mln CAD |
-123,3% |
2025 |
| 411 | ALMSAlumis Inc. |
24,1 mln USD |
-1011,7% |
2025 |
| 412 | BDMDBaird Medical Investment Holdings Ltd |
22,5 mln USD |
-121,0% |
2025 |
| 413 | NAMSNewAmsterdam Pharma Co N.V. |
22,5 mln USD |
-905,7% |
2025 |
| 414 | DRIODarioHealth Corp. |
22,4 mln USD |
-186,6% |
2025 |
| 415 | ALECAlector, Inc. |
21 mln USD |
-679,2% |
2025 |
| 416 | ZJYLJin Medical International Ltd. |
20,7 mln USD |
5,8% |
2025 |
| 417 | SCYXScynexis Inc |
20,6 mln USD |
-41,8% |
2025 |
| 418 | MDAISpectral AI, Inc. |
19,7 mln USD |
-38,5% |
2025 |
| 419 | SLGLSol-Gel Technologies Ltd. |
19,4 mln USD |
-31,6% |
2025 |
| 420 | POCIPrecision Optics Corporation, Inc. |
19,1 mln USD |
-30,3% |
2025 |
| 421 | LENZLENZ Therapeutics, Inc. |
19,1 mln USD |
-430,3% |
2025 |
| 422 | NEPHNephros Inc |
18,8 mln USD |
6,4% |
2025 |
| 423 | OABIOmniAb, Inc. |
18,7 mln USD |
-347,0% |
2025 |
| 424 | MDWDMediWound Ltd. |
17 mln USD |
-140,8% |
2025 |
| 425 | PTHSPelthos Therapeutics Inc. |
16,8 mln USD |
-257,9% |
2025 |
| 426 | ZYBTZhengye Biotechnology Holding Ltd |
16,6 mln USD |
-60,0% |
2025 |
| 427 | QUREuniQure N.V. |
16,1 mln USD |
-1236,0% |
2025 |
| 428 | PROFProfound Medical Corp. |
16,1 mln USD |
-264,4% |
2025 |
| 429 | PRQRProQR Therapeutics N.V. |
15,9 mln € |
-265,2% |
2025 |
| 430 | RLAYRelay Therapeutics, Inc. |
15,4 mln USD |
-1800,6% |
2025 |
| 431 | LCTXLineage Cell Therapeutics, Inc. |
14,6 mln USD |
-436,5% |
2025 |
| 432 | IRDOpus Genetics, Inc. |
14,2 mln USD |
-349,3% |
2025 |
| 433 | ABUSArbutus Biopharma Corp |
14,1 mln USD |
-237,9% |
2025 |
| 434 | PYXSPyxis Oncology, Inc. |
13,9 mln USD |
-574,5% |
2025 |
| 435 | HYPRHyperfine, Inc. |
13,6 mln USD |
-262,3% |
2025 |
| 436 | CVCapsoVision, Inc |
13,6 mln USD |
-186,8% |
2025 |
| 437 | TNXPTonix Pharmaceuticals Holding Corp. |
13,1 mln USD |
-946,2% |
2025 |
| 438 | NNOXNano-X Imaging Ltd. |
13 mln USD |
-576,1% |
2025 |
| 439 | EVMNEvommune, Inc. |
13 mln USD |
-529,8% |
2025 |
| 440 | ELUTElutia Inc. |
12,3 mln USD |
434,2% |
2025 |
| 441 | PRLDPrelude Therapeutics Inc |
12,1 mln USD |
-819,6% |
2025 |
| 442 | CRBUCaribou Biosciences, Inc. |
11,2 mln USD |
-1327,4% |
2025 |
| 443 | CBIOCrescent Biopharma, Inc. |
10,8 mln USD |
-1419,6% |
2025 |
| 444 | TCRXTScan Therapeutics, Inc. |
10,3 mln USD |
-1256,8% |
2025 |
| 445 | ACOGAlpha Cognition Inc. |
10,2 mln USD |
-202,2% |
2025 |
| 446 | ZBIOZenas BioPharma, Inc. |
10 mln USD |
-3777,4% |
2025 |
| 447 | JANXJanux Therapeutics, Inc. |
10 mln USD |
-1136,3% |
2025 |
| 448 | TSHATaysha Gene Therapies, Inc. |
9,8 mln USD |
-1115,3% |
2025 |
| 449 | PGENPrecigen, Inc. |
9,7 mln USD |
-2588,2% |
2025 |
| 450 | PRTAProthena Corp Public Ltd Co |
9,7 mln USD |
-2520,6% |
2025 |